Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Patient preferences for treatment characteristics of Janus kinase inhibitors for alopecia areata: a discrete choice experiment.
Journal: The Journal of dermatological treatment
Published: May 15, 2026
Real-World Benefit of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: Findings from a Systematic Literature Review and Meta-Analysis.
Journal: Dermatology and therapy
Published: October 31, 2025
Real-World Treatment Patterns of Patients with Basal Cell Carcinoma Using Sonidegib and Vismodegib: Discontinuation Rates and Clinical Conditions During Treatment.
Journal: Dermatology and therapy
Published: September 29, 2025
A Discrete Choice Experiment of Clinician Preferences Among Attributes of Approved Janus Kinase Inhibitors for Alopecia Areata.
Journal: Advances in therapy
Published: September 19, 2025
Correction: Biologics for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Network Meta-analysis.
Journal: Dermatology and therapy
Published: August 25, 2025
Biologics for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Network Meta-analysis.
Journal: Dermatology and therapy
Published: February 17, 2025
Improvement in Patient-reported Symptoms and Satisfaction with Tildrakizumab in a Real-world Study in Patients with Moderate-to-severe Plaque Psoriasis.
Journal: The Journal of clinical and aesthetic dermatology
Published: October 24, 2024
Tildrakizumab Real-World Effectiveness and Safety Over 64 Weeks in Patients With Moderate-to-Severe Plaque Psoriasis.
Journal: Journal of drugs in dermatology : JDD
Published: August 02, 2024
Improvements in Psoriasis-Related Work Productivity with Tildrakizumab: Results from a Phase 4 Real-World Study in Patients with Moderate-to-Severe Plaque Psoriasis.
Journal: Dermatology and therapy
Published: January 29, 2024
Dupilumab Efficacy in Patients with Type 2 Asthma with and without Elevated Blood Neutrophils.
Journal: Journal of immunology research
Published: August 26, 2022
Racial and Ethnic Minorities at the Highest Risk of Uncontrolled Moderate-to-Severe Asthma: A United States Electronic Health Record Analysis.
Journal: Journal of asthma and allergy
Published: July 26, 2022
Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events.
Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: March 16, 2020
Last Updated: 09/26/2026